Outlook Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.

CEO

Lawrence A. Kenyon

CEOLawrence A. Kenyon

Employees

Employees23

Headquarters

Iselin, New Jersey

HeadquartersIselin, New Jersey

Founded

2010

Founded2010

Employees

Employees23

OTLK Key Statistics

Market cap

54.64M

Market cap54.64M

Price-Earnings ratio

-0.21

Price-Earnings ratio-0.21

Dividend yield

—

Dividend yield—

Average volume

521.22K

Average volume521.22K

High today

$1.91

High today$1.91

Low today

$1.62

Low today$1.62

Open price

$1.77

Open price$1.77

Volume

305.45K

Volume305.45K

52 Week high

$9.25

52 Week high$9.25

52 Week low

$0.87

52 Week low$0.87

People also own

Based on the portfolios of people who own OTLK. This list is generated using Robinhood data, and it’s not a recommendation.